|Bid||0.9600 x 0|
|Ask||0.9700 x 0|
|Day's Range||0.9500 - 0.9700|
|52 Week Range||0.8900 - 5.7000|
|Beta (5Y Monthly)||3.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.
Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.
The cannabis industry in Canada hasn't been in good shape for some time. Growth is almost nonexistent, profits are elusive, and stock prices of marijuana producers have been nosediving. What's particularly telling are the moves of two of the industry's leaders, Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC).